表紙
市場調查報告書

被套細胞淋巴瘤治療藥的全球市場:2019年∼2023年

Global Mantle Cell Lymphoma Therapeutics Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 895031
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
Back to Top
被套細胞淋巴瘤治療藥的全球市場:2019年∼2023年 Global Mantle Cell Lymphoma Therapeutics Market 2019-2023
出版日期: 2019年07月24日內容資訊: 英文 131 Pages
簡介

被套細胞淋巴瘤治療藥,聯合治療和單劑療法。2018年,聯合治療市場區隔獲得了最大的市場佔有率。預計這個趨勢在預測期間內也將持續。藥物抗性低,聯合治療的開發與商品化的增加等要素,在市場區隔維持主導地位有很大幫助。還有全球被套細胞淋巴瘤治療藥市場,由於最近的認證,標靶治療的引進,老年人口的增加等市場成長要素,在預測期間內預計將以7%以上的年複合成長率擴大。然而,可利用的治療藥的副作用,治療的獲取限制,及嚴格的法規存在等,有可能妨礙在預測期間內被套細胞淋巴瘤治療藥產業的成長。

本報告提供全球被套細胞淋巴瘤治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 聯合治療
  • 單劑療法
  • 市場機會:各產品

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 新的治療方法的登場
  • 研究津貼及財政支援
  • 專用藥的指定

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Allergan Plc
  • AstraZeneca Plc
  • Celgene Corp.
  • Johnson & Johnson Services Inc.
  • 武田藥品工業

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31758

About this market

Mantle cell lymphoma therapeutics are available in combination therapy and monotherapy. Technavio's mantle cell lymphoma therapeutics market analysis considers sales from the combination therapy and monotherapy segments. Our analysis also considers the sales of mantle cell lymphoma therapeutics in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the reduced drug resistance and rising development and commercialization of combination therapies will significantly help the market segment in maintaining its leading position. Also, our global mantle cell lymphoma therapeutics report has observed market growth factors such as recent approvals, introduction of targeted therapies, and growth of geriatric population. However, adverse effects of available therapeutics, limited access to treatment, and presence of stringent regulations may hamper the growth of the mantle cell lymphoma therapeutics industry over the forecast period.

Overview

Recent approvals

The significant unmet need for the treatment of mantle cell lymphoma has given the market vendors scope to develop reliable therapeutics. The rising formulation of therapeutics has prompted many approvals in the last few years, increasing the sales of vendors. As a result, recent approvals will lead to the expansion of the mantle cell lymphoma therapeutics market at a CAGR of over 7% during the forecast period.

Advent of novel therapies

Vendors are formulating advanced therapeutics to cater to the market demand. For instance, kinase inhibitors and gene therapies exhibit high efficacy, increasing their demand. Therefore, this trend will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global mantle cell lymphoma therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global mantle cell lymphoma therapeutics market is concentrated. Technavio's robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading mantle cell lymphoma therapeutics manufacturers, which include Allergan Plc, AstraZeneca Plc, Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the mantle cell lymphoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Advent of novel therapies
  • Research grants and funding
  • Special drug designations

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Allergan Plc
  • AstraZeneca Plc
  • Celgene Corp.
  • Johnson & Johnson Services Inc.
  • Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Combination therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Monotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Monotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Proportion of geriatric population in Asia 2007 and 2017
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in ROW
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Pipeline molecules
  • Exhibit 44: Growth in geriatric population 2013-2017 (%)
  • Exhibit 45: Side effects of drugs treating mantle cell lymphoma
  • Exhibit 46: Impact of drivers and challenges
  • Exhibit 47: Drug designations
  • Exhibit 48: Recently approved drug designations to drug candidates aimed to treat mantle cell lymphoma
  • Exhibit 49: Vendor landscape
  • Exhibit 50: Landscape disruption
  • Exhibit 51: Vendors covered
  • Exhibit 52: Vendor classification
  • Exhibit 53: Market positioning of vendors
  • Exhibit 54: Allergan Plc - Vendor overview
  • Exhibit 55: Allergan Plc - Business segments
  • Exhibit 56: Allergan Plc - Organizational developments
  • Exhibit 57: Allergan Plc - Geographic focus
  • Exhibit 58: Allergan Plc - Segment focus
  • Exhibit 59: Allergan Plc - Key offerings
  • Exhibit 60: Allergan Plc - Key customers
  • Exhibit 61: AstraZeneca Plc - Vendor overview
  • Exhibit 62: AstraZeneca Plc - Product segments
  • Exhibit 63: AstraZeneca Plc - Organizational developments
  • Exhibit 64: AstraZeneca Plc - Geographic focus
  • Exhibit 65: AstraZeneca Plc - Key offerings
  • Exhibit 66: AstraZeneca Plc - Key customers
  • Exhibit 67: Celgene Corp. - Vendor overview
  • Exhibit 68: Celgene Corp. - Business segments
  • Exhibit 69: Celgene Corp. - Organizational developments
  • Exhibit 70: Celgene Corp. - Geographic focus
  • Exhibit 71: Celgene Corp. - Key offerings
  • Exhibit 72: Celgene Corp. - Key customers
  • Exhibit 73: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 74: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 75: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 76: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 77: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 78: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 79: Johnson & Johnson Services, Inc. - Key customers
  • Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 85: Takeda Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 86: Validation techniques employed for market sizing
  • Exhibit 87: Definition of market positioning of vendors
Back to Top